Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Asset Writedowns and Impairment (2019 - 2024)

Historic Asset Writedowns and Impairment for Heron Therapeutics (HRTX) over the last 6 years, with Q3 2024 value amounting to $828000.0.

  • Heron Therapeutics' Asset Writedowns and Impairment rose 43766.23% to $828000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $4.4 million, marking a year-over-year increase of 71605.17%. This contributed to the annual value of $617000.0 for FY2023, which is 19521.53% up from last year.
  • Heron Therapeutics' Asset Writedowns and Impairment amounted to $828000.0 in Q3 2024, which was up 43766.23% from $3.3 million recorded in Q2 2024.
  • Over the past 5 years, Heron Therapeutics' Asset Writedowns and Impairment peaked at $3.3 million during Q2 2024, and registered a low of $8000.0 during Q3 2020.
  • In the last 5 years, Heron Therapeutics' Asset Writedowns and Impairment had a median value of $124000.0 in 2021 and averaged $337894.7.
  • As far as peak fluctuations go, Heron Therapeutics' Asset Writedowns and Impairment soared by 281111.11% in 2020, and later plummeted by 8422.39% in 2021.
  • Quarter analysis of 5 years shows Heron Therapeutics' Asset Writedowns and Impairment stood at $786000.0 in 2020, then crashed by 84.22% to $124000.0 in 2021, then crashed by 36.29% to $79000.0 in 2022, then soared by 94.94% to $154000.0 in 2023, then soared by 437.66% to $828000.0 in 2024.
  • Its last three reported values are $828000.0 in Q3 2024, $3.3 million for Q2 2024, and $170000.0 during Q1 2024.